Sarat Chandarlapaty, PhD, MD

Highlights

1
The Journal of clinical investigation · 2024
SCSarat Chandarlapaty
PMID: 37883178PMCID: PMC10760953DOISenior author19 citations

155

3 grants

PI
Overcoming Resistance to Targeted Therapy in Breast Cancer
NCI · 2025–2032 · via NIH RePORTER
R35CA305347-02
MPI
MSK SPORE in Genomic Instability in Breast Cancer
NCI · 2020–2031 · via NIH RePORTER
P50CA247749-06A1
MPI
Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.
NCI · 2025–2030 · via NIH RePORTER
R01CA296285-02

Completed grants (6)

PI
HER2-mediated delivery of cytotoxic agents in solid tumors
NCI · 2021–2025 · via NIH RePORTER
R01CA249666-04
PI
Defining the impact of mutant oncogene zygosity
NCI · 2020–2025 · via NIH RePORTER
R01CA245069-05
MPI
Defining mechanisms of resistance to hormonal therapy in breast cancer
NCI · 2018–2024 · via NIH RePORTER
R01CA234361-05
PI
Therapeutic approaches to ER mutant breast cancer
NCI · 2017–2022 · via NIH RePORTER
R01CA204999-05
PI
Implications and Vulnerabilities of APOBEC Mutagenesis in Breast Cancer
NCI · 2020–2020 · via NIH RePORTER
R01CA244812-01
PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
NCI · 2009–2014 · via NIH RePORTER
K08CA134833-05